Abstract

Urologic cancers include cancers of the bladder, kidney, prostate, and testes, with common molecular features spanning different types. Here, we show that 1954 urologic cancers can be classified into nine major genomic subtypes, on the basis of multidimensional and comprehensive molecular characterization (including DNA methylation and copy number, and RNA and protein expression). Tissue dominant effects are first removed computationally in order to define these subtypes, which reveal common processes—reflecting in part tumor microenvironmental influences—driving cellular behavior across tumor lineages. Six of the subtypes feature a mixture of represented cancer types as defined by tissue or cell of origin. Differences in patient survival and in the manifestation of specific pathways—including hypoxia, metabolism, NRF2-ARE, Hippo, and immune checkpoint—can further distinguish the subtypes. Immune checkpoint markers and molecular signatures of macrophages and T cell infiltrates are relatively high within distinct subsets of each cancer type studied. The pan-urologic cancer genomic subtypes would facilitate information sharing involving therapeutic implications between tissue-oriented domains.

Details

Title
Pan-urologic cancer genomic subtypes that transcend tissue of origin
Author
Chen, Fengju 1 ; Zhang, Yiqun 1 ; Bossé, Dominick 2 ; Lalani, Aly-Khan A 2   VIAFID ORCID Logo  ; A Ari Hakimi 3 ; Hsieh, James J 4   VIAFID ORCID Logo  ; Choueiri, Toni K 2 ; Gibbons, Don L 5 ; Ittmann, Michael 6 ; Creighton, Chad J 7 

 Dan L. Duncan Comprehensive Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX, USA 
 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 
 Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
 Molecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO, USA 
 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 
 Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA 
 Dan L. Duncan Comprehensive Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA 
Pages
1-15
Publication year
2017
Publication date
Aug 2017
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1925833066
Copyright
© 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.